Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

LESSONS LEARNED. Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing. Safety was documented, although dose escalation was...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Reilly, Eileen M., Roach, James, Miller, Paul, Yu, Kenneth H., Tjan, Catherine, Rosano, Molly, Krause, Silva, Avery, William, Wolf, Julie, Flaherty, Keith, Nix, Darrell, Ryan, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728039/
https://www.ncbi.nlm.nih.gov/pubmed/29158367
http://dx.doi.org/10.1634/theoncologist.2017-0472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728039/
https://www.ncbi.nlm.nih.gov/pubmed/29158367
http://dx.doi.org/10.1634/theoncologist.2017-0472

Ejemplares similares